Jeremy Rosenblum

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice”.

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2020-002267

N/A

0DataRank · unranked

41 citations

Gaurav Nayyar, Susiyan Jiang, Jeremy Rosenblum, Patrick Soon‐Shiong, Jeffrey T. Safrit +3 more

Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective

EJC Paediatric Oncology(2023)10.1016/j.ejcped.2023.100024

N/A

0DataRank · unranked

11 citations

Murali Chintagumpala, Jin Piao, Kenneth S. Chen, Rachana Shah, Robyn D. Gartrell +15 more

Factors Associated With Rare Pediatric Cancer Trial Enrollment: A Report From the Children's Oncology Group Rare Tumors Committee

Pediatric Blood & Cancer(2025)10.1002/pbc.32164

N/A

0DataRank · unranked

1 citations

Jin Piao, Lindsay Younis, Reto M. Baertschiger, Kenneth S. Chen, Emily Christison‐Lagay +16 more